HANSOH PHARMA's stock price surged 7.32% during Tuesday's intraday trading session, reflecting strong investor response to the company's latest financial performance.

The significant price movement follows the company's announcement of its 2025 annual results, which showed robust growth across key financial metrics. The pharmaceutical group reported revenue of RMB 150.28 billion, representing a 22.57% year-on-year increase, while profit attributable to owners reached RMB 55.55 billion, marking an impressive 27.07% growth compared to the previous year.

Notably, revenue from innovative drugs and partnered products reached approximately RMB 123.54 billion, accounting for about 82.2% of total revenue and establishing this segment as the core driver for the group's sustainable performance growth. The company has also proposed a final dividend of HK 20.0 cents per share.